我国DTP药房发展过程及原因分析

Analysis on the Development Process and Causes of DTP Pharmacy in China

我国Direct to Patient(DTP)药房的发展可追溯到20世纪六七十年代,但由于当时的经济体制未能得到进一步的发展。进入21世纪后,由于社会疾病谱的转变、药品临床化时间过长以及新一轮医改启动等原因为DTP药房的发展带来了市场与政策的优势,但目前而言其缺乏顶层的行业规范,相关准入标准过高以及患者认知度等在一定程度上制约了DTP药房的发展。因此,从顶层设计的行业规章制度入手、加强DTP药房与第三方物流企业的合作以及增加自身的服务内容是保证DTP药房发展的关键。

The development of China’s Direct to Patient(DTP) pharmacy can be traced back to the 1960 s and 1970 s, but the economic system at that time could not be further developed. After entering the 21 st century, due to the transformation of social disease spectrum, the long time of drug clinicalization and the launch of a new round of medical reform, the market and policy advantages have been brought about by the development of DTP pharmacies. However, at present, it lacks the top-level industry norms. The excessive access standards and patient awareness have restricted the development of DTP pharmacies to some extent. Therefore, starting from the top-level design of industry rules and regulations, strengthening the cooperation between DTP pharmacies and third-party logistics companies and increasing their own service content is the key to ensuring the development of DTP pharmacies.